Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Arizona Tribune - Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025, after the market close on Wednesday, May 14, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, May 14, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Text size:

Conference Call Details

Date and Time: Wednesday, May 14, 2025, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 314386.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/52282, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until May 28, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52282.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum or Roger Weiss
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

D.Johnson--AT

RBGPF	0%	61.3	$
CMSC	0.02%	22.07	$
GSK	1.67%	51.96	$
BCE	-0.3%	23.13	$
RELX	-0.32%	31.05	$
AZN	1.06%	184.99	$
BTI	0.88%	61.935	$
RIO	1.13%	95.1	$
NGG	0.56%	83.3	$
CMSD	-0.69%	21.87	$
RYCEF	3.4%	18.8	$
BCC	1.55%	78.88	$
JRI	0.59%	12.645	$
BP	0.05%	37.88	$
VOD	0.29%	13.85	$

Arizona Tribune - Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Featured

US Supreme Court hands win to Bayer in weedkiller litigation

HRW denounces Turkey arrests ahead of NATO summit

Venezuelans trapped alive after twin quakes kill at least 164

Venezuela twin quakes kill at least 164 with many trapped under rubble